Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nasodine is a 0.5% povidone-iodine (PVP-I) nasal spray developed by Firebrick Pharma. As a broad-spectrum topical antiseptic, povidone-iodine inactivates a wide range of respiratory pathogens, including viruses and bacteria, through the iodination and oxidation of essential proteins and lipids. The product is administered intranasally and is intended for the prevention and treatment of the common cold, as well as for the reduction of viral shedding and airborne germ transmission. While it has undergone Phase I, II, and III clinical trials for therapeutic indications, it has been marketed in the United States as a 'nasal hygiene' product without therapeutic claims. The formulation is designed for rapid action, with studies demonstrating the inactivation of most respiratory viruses in under 60 seconds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nasodine.